XCE853

XCE853 is a first-in-class, synthetic small molecule inhibitor of protein disulfide isomerase (PDI), an enzyme involved in cancer cell metabolism and survival. Developed by Oregon Therapeutics and co-developed with Lantern Pharma, XCE853 selectively induces autophagy in cancer cells by inhibiting PDI, a target highly expressed in various tumor types and associated with drug resistance. Preclinical studies have demonstrated robust antitumor activity across multiple cancer models—including ovarian, pancreatic, prostate, colorectal, non-small cell lung cancers (NSCLC), renal cell carcinoma (RCC), breast cancer, head and neck cancers, leukemia—and particularly against tumors resistant to current chemotherapies. The drug is orally bioavailable and has shown efficacy at low nanomolar concentrations in vitro as well as significant tumor growth inhibition in vivo xenograft models. The primary development focus is on drug-resistant ovarian and advanced pancreatic cancers; additional potential indications include liver cancer and several orphan or pediatric CNS cancers[1][2][4][5][6][7][8].